Stryker Corporation $SYK Shares Bought by National Pension Service

National Pension Service raised its holdings in Stryker Corporation (NYSE:SYK) by 2.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 721,186 shares of the medical technology company’s stock after buying an additional 16,962 shares during the quarter. National Pension Service owned about 0.19% of Stryker worth $227,058,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. VanderPol Investments L.L.C. raised its position in shares of Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after purchasing an additional 28 shares during the last quarter. KCM Investment Advisors LLC grew its position in Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after purchasing an additional 28 shares during the last quarter. Rossby Financial LCC increased its stake in Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after purchasing an additional 28 shares in the last quarter. Tcfg Wealth Management LLC increased its stake in Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares in the last quarter. Finally, ICW Investment Advisors LLC raised its holdings in shares of Stryker by 0.6% in the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock worth $1,791,000 after buying an additional 30 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

NYSE:SYK opened at $269.98 on Friday. The firm’s fifty day moving average is $325.65 and its two-hundred day moving average is $326.84. The firm has a market cap of $103.56 billion, a price-to-earnings ratio of 27.98, a PEG ratio of 1.72 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a one year low of $269.64 and a one year high of $392.55.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts expect that Stryker Corporation will post 15.03 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.3%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda Stryker sold 300,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the sale, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider directly owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by company insiders.

Analyst Ratings Changes

SYK has been the topic of a number of research analyst reports. Wells Fargo & Company dropped their price objective on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a report on Wednesday. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Evercore set a $350.00 price objective on Stryker in a report on Monday, July 6th. JPMorgan Chase & Co. reduced their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Citigroup dropped their target price on Stryker from $399.00 to $360.00 and set a “buy” rating on the stock in a research report on Thursday. Eighteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $380.40.

About Stryker

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.